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ABSTRACT 22 
Host restriction factor TRIM5 inhibits retroviral transduction in a species-specific 23 
manner by binding to and destabilizing the retroviral capsid lattice before reverse 24 
transcription is completed. But the restriction mechanism may not be that simple 25 
since TRIM5 E3 ubiquitin ligase activity, the proteasome, autophagy, and TAK1-26 
dependent AP-1 signaling have been suggested to contribute to restriction. Here 27 
we show that, among a panel of seven primate and Carnivora TRIM5 28 
orthologues, each of which has potential for potent retroviral restriction activity, 29 
all activated AP-1 signaling. In contrast, TRIM family paralogues most closely 30 
related to TRIM5 did not. While each primate species has a single TRIM5 gene, 31 
mice have at least seven TRIM5 homologues that cluster into two groups, 32 
Trim12a, b, and c, and Trim30a, b, c, and d. The three Trim12 proteins activated 33 
innate immune signaling, while the Trim30 proteins did not, though none of the 34 
murine Trim5 homologues restricted any of a panel of cloned retroviruses. To 35 
determine if any mouse TRIM5 homologues had potential for restriction activity 36 
each was fused to the HIV-1 CA binding protein cyclophilin A (CypA). The three 37 
Trim12-CypA fusions all activated AP-1 and restricted HIV-1 transduction, 38 
whereas the Trim30-CypA fusions did neither. AP-1 activation and HIV-1 39 
restriction by the Trim12-CypA fusions was inhibited by disruption of TAK1. 40 
Overall then, these experiments demonstrate that there is a strong correlation 41 
between TRIM5 retroviral restriction activity and the ability to activate TAK1-42 
dependent innate immune signaling. 43 
 44 
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IMPORTANCE 45 
 46 
The importance of retroviruses for the evolution of susceptible host organisms 47 
cannot be overestimated. 8% of the human genome is retrovirus sequence, fixed 48 
in the germline during past infection. Understanding how metazoa protect their 49 
genomes from mutagenic retrovirus infection is therefore of fundamental 50 
importance to biology. TRIM5 is a cellular protein that protects host genome 51 
integrity by disrupting the retroviral capsid as it transports viral nucleic acid to the 52 
host cell nucleus. Previous data suggest that innate immune signaling 53 
contributes to TRIM5-mediated restriction. Here we show that activation of innate 54 
immune signaling is conserved among primate and carnivore TRIM5 55 
orthologues, and among 3 of the 7 mouse Trim5 homologues, and that such 56 
activity is required for TRIM5-mediated restriction activity.  57 
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INTRODUCTION 58 
When a retrovirus fuses its membrane with a susceptible target cell it releases 59 
the virion core into the host cell cytoplasm (1). The core is composed of a capsid 60 
(CA) protein lattice, within which is the viral RNA. The viral RNA is reverse 61 
transcribed into cDNA by the viral reverse transcriptase (RT). Via a poorly 62 
characterized mechanism the viral cDNA is transferred to the host cell nucleus. 63 
The viral integrase protein (IN) then ligates the viral cDNA into the host 64 
chromosomal DNA to generate the provirus, thus completing the transduction 65 
process. 66 
 Host species that are susceptible to retroviral infection encode factors that 67 
block retroviral transduction, perhaps because these early events in the retroviral 68 
life cycle result in mutation of the host genome that is potentially catastrophic. 69 
The genes encoding these antiviral factors are among the fastest evolving in the 70 
primate genome. The fact that the greatest polymorphism tends to be found in 71 
those parts of the gene that encode protein surfaces interacting directly with 72 
retroviral proteins, along with the fact that retroviruses encode proteins that 73 
specifically degrade many of these antiviral factors, supports the contention that 74 
the evolution of these antiviral genes is driven by retroviral challenge (1-3).  75 
One such antiretroviral factor is called TRIM5, a member of the large 76 
tripartite motif family, of which humans have 100 genes (4). Like all TRIM family 77 
members, TRIM5 consists of a RING E3 ubiquitin ligase domain, a B box 78 
domain, and an extended, central, alpha-helical domain (5). The polymorphic C-79 
terminus comes as either a PRY-SPRY or a cyclophilin domain, either of which 80 
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constitutes the main species-specificity determinant for CA recognition. The 81 
protein is believed to reside in the cell cytoplasm as a dimer where it meets the 82 
incoming retroviral CA lattice. If the CA lattice is recognized, TRIM5 forms a 83 
complementary lattice (6) that promotes premature disassembly of the viral CA 84 
lattice (7), blocking reverse transcription, nuclear entry, and integration.  85 
It appears, though, that CA recognition, and TRIM5 lattice formation, are 86 
not sufficient for full TRIM5 restriction activity. Several lines of evidence suggest 87 
that proteasomes contribute to the restriction mechanism. Proteasome inhibitors 88 
release reverse transcription from the TRIM5-mediated block, though a block to 89 
nuclear entry still remains (8). TRIM5 binds to proteasome components and 90 
cytoplasmic bodies co-localize with proteasomes in cells after challenge with 91 
TRIM5-sensitive viruses (9, 10). These results suggest that at least some aspect 92 
of the restriction mechanism involves ubiquitination of the virion capsid with 93 
subsequent protein degradation in the proteasome. Additionally, TRIM5 has been 94 
reported to interact with cellular regulators of autophagy and to deliver restriction-95 
sensitive retroviral capsids to autophagosomes for destruction (11, 12).  96 
E3 ubiquitin ligase activity associated with the N-terminal RING domain 97 
also contributes to restriction activity (13). Though ubiquitinated retroviral capsid 98 
proteins have never been detected within cells in a TRIM5-dependent manner, it 99 
is still possible that the RING domain contributes to restriction activity by 100 
ubiquitinating the retroviral capsid. Alternatively, it has been reported that TRIM5 101 
activates innate immune signaling (14-16) and that TRIM5 generates free K63-102 
linked ubiquitin chains that activate the TAK1 (MAP3K7) kinase complex in vitro 103 
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(15). Knockdown of TAK1, or of the specific E2 enzymes required for TRIM5 to 104 
generate K63-linked ubiquitin chains, attenuates human or owl monkey TRIM5-105 
mediated restriction (15). These results suggest that TAK1-dependent innate 106 
immune signaling, activated by TRIM5 E3 ubiquitin ligase activity, may also 107 
contribute to the restriction mechanism.  108 
TRIM5 retroviral restriction activity has been most extensively studied 109 
among primates (2), each of which have one TRIM5 gene, the products of which 110 
have restriction specificity for different subsets of retroviruses (17). An 111 
extraordinary expansion of the TRIM5 locus is found in rodents, such that rats 112 
have 3 TRIM5 genes and mice have at least seven (18). Given the panel of 113 
retroviral vectors that are currently available for phenotypic testing, none were 114 
found to be restricted by any of the rodent genes tested (18). This could mean 115 
that the rodent TRIM5 genes lack retroviral restriction activity or that a restriction-116 
sensitive virus has just not been found. 117 
Here we tested 18 different TRIM proteins for the ability to activate innate 118 
immune signaling. The panel included seven murine Trim5 homologues (Table 119 
1), which, in addition, were fused to CypA in order to determine if they were 120 
capable retroviral restriction.  121 
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RESULTS 122 
 123 
Activation of innate immune signaling is a conserved feature of TRIM5 124 
orthologues from Primates, Carnivora, and Rodentia. To determine if the 125 
activation of innate immune signaling is a conserved property among TRIM5 126 
family members, TRIM5alpha from Homo sapiens, Macaca mulata, 127 
Cercopithecus aethiops and Cercopithecus tantalus, TRIM5-cyclophilin A fusions 128 
from Aotus trivirgatus and Macaca nemestrina, and TRIM5 from Felis catus were 129 
overexpressed by plasmid transfection of HEK293 cells.  In each case, an AP-1 130 
luciferase reporter was activated, with the magnitude ranging from 25- 131 
(Cercopithecus aethiops) to 262- (Aotus trivirgatus) fold above the levels with 132 
empty expression plasmid (Fig. 1A). In contrast, the paralogues most closely 133 
related to human TRIM5alpha, either had undetectable (TRIM6 and TRIM22) or 134 
minimal (TRIM34) activity (Fig. 1B). The more distantly related human TRIM25, a 135 
protein required for RIG-I-mediated signaling (19), was nearly as potent as 136 
TRIM5alpha (Fig. 1B). 137 
The Trim5 locus in rodents expanded by successive duplications such that 138 
the C57BL/6J mouse strain possesses seven Trim5 gene homologues (Table 1), 139 
Trim12a, Trim12b, Trim12c, Trim30a, Trim30b, Trim30c, and Trim30d (18). 140 
Coding sequence for each of these genes was cloned into an expression vector. 141 
When transfected into HEK293 cells, Trim12A, Trim12B and Trim12C activated 142 
AP-1 as well as human TRIM5α (Fig. 1C). In contrast, none of the Trim30 genes 143 
caused significant induction of AP-1 (Fig. 1C). 144 
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Trim12b, Trim12c, Trim30a, Trim30c, and Trim30d each are predicted to 145 
encode a full tripartite motif protein with the PRYSPRY domain typical of the 146 
TRIM5alpha isoform (Table 1). Trim12a and Trim30b encode the core tripartite 147 
motif protein without the PRYSPRY domain. In each case, the gel mobility of the 148 
encoded proteins was as expected (Fig. 1D). Though steady-state levels of 149 
Trim30c protein were relatively low, the levels of Trim30a, Trim30b, and Trim30d 150 
were all higher than the levels of the Trim12 proteins (Fig. 1D). Thus, steady-151 
state protein levels did not account for the reduced ability of the Trim30 gene to 152 
stimulate AP-1. 153 
HEK293 cells were transfected with expression plasmids encoding each of 154 
the murine Trim proteins with a C-terminal myc epitope. The transfected cells 155 
were probed by indirect immunofluorescence and visualized by confocal 156 
microscopy. Trim12a, Trim12b, and Trim12c all formed distinct cytoplasmic 157 
bodies (Fig. 2). In contrast, though some cytoplasmic bodies were observed with 158 
Trim30a, for the most part relatively diffuse cytoplasmic staining was observed 159 
with the Trim30 proteins (Fig. 2). These results indicate that all Trim5 160 
homologues that activate innate immune signaling form discrete cytoplasmic 161 
bodies.  162 
 163 
Retroviral restriction activity correlates with the ability to activate 164 
signaling. In an attempt to detect retroviral restriction activity associated with the 165 
mouse Trim5 homologues, CRFK cell lines were generated that stably expressed 166 
each of them, using previously described methods (20). These lines were then 167 
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challenged with single-cycle vectors for HIV-1, HIV-2, SIVMAC, EIAV, and 168 
Moloney murine leukemia virus. In agreement with previous attempts by others 169 
(18) no restriction activity was detected with any of the viruses. However, the 170 
strong signature of positive selection reported for the rodent Trim5 homologues 171 
(18) suggests that, as demonstrated with the primate TRIM5 orthologues (2, 17), 172 
the rodent genes have also been selected to protect against retroviral infection, 173 
and that the viruses restricted by them remain to be identified.  174 
 TRIM5-mediated retroviral restriction activity depends upon multiple 175 
biochemical functions provided by independently-acting modular domains within 176 
the protein (5). The RING domain exhibits E3 ubiquitin ligase activity. The central 177 
anti-parallel, alpha-helical stalk (coiled-coil domain), along with the B-Box 178 
domain, dimerizes and multimerizes TRIM5. The polymorphic C-terminus, either 179 
a PRYSPRY or cyclophilin A domain, binds directly to the retroviral CA lattice 180 
and therefore is the main CA-specificity determinant. Lack of retroviral restriction 181 
activity could simply result from inability of a given TRIM5 protein to bind to the 182 
CA lattice of the particular virus under investigation. To determine if this was the 183 
case, the RING, the B Box, and the Coiled-Coil domains (RBCC) of the murine 184 
Trim5 homologues were fused to the well-characterized HIV-1 CA binding protein 185 
cyclophilin A (CypA), as has been done with other TRIM proteins (21, 22). As a 186 
control, CypA-H126Q was used; this mutant protein does not bind to the HIV-1 187 
CA (23). 188 
 When transfected into HEK293 cells, Trim12a-CypA and Trim12a-CypA-189 
H126Q each induced the AP-1 luciferase reporter about 100-fold, similar to 190 
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Trim12a without the fusion (Fig. 3A). In contrast, Trim30a had minimal effect on 191 
the reporter, and when fused to CypA there was minimal increase in activity over 192 
the unfused protein (Fig. 3A). Trim12b induced the AP-1 reporter 50-fold and the 193 
Trim12b-CypA fusion protein induced it 200-fold (Fig. 3B). Trim12c and Trim12c-194 
CypA each induced AP-1 over 150-fold (Fig. 3B). Trim30b and Trim30b-CypA 195 
had minimal effect on AP-1 activity (Fig. 3B). While the CypA fusion caused 196 
some increase in AP-1 activity for Trim12b and Trim30a, in general the effect of 197 
the CypA fusions on signaling was similar to that of the unfused proteins. 198 
 To determine if the CypA fusion proteins were able to restrict HIV-1, a 199 
lentiviral expression vector (Fig. 3C) was used to transduce highly permissive 200 
CRFK cells. This bicistronic vector confers puromycin resistance and transduced 201 
cells were selected in pools. These were then challenged with a three-part, VSV 202 
G-pseudotyped, HIV-1 vector bearing a GFP-reporter genome. Cells expressing 203 
the Trim12a-CypA fusion gene were about 100-fold less permissive for 204 
transduction than were the cells bearing either empty vector, Trim12a, or 205 
Trim12a fused to the CypA-H126Q mutant (Fig. 3D). In contrast, Trim30a or 206 
Trim30a fused to CypA had no detectable restriction activity (Fig. 3D). Trim12b-207 
CypA and Trim12c-CypA each had restriction comparable to Trim12a-CypA, 208 
though neither unfused protein nor Trim30b-CypA had clear restriction activity 209 
(Fig. 3E). Steady-state protein levels for the CypA protein fusions did not explain 210 
the inability of the Trim30-CypA fusion proteins to restrict HIV-1, in that protein 211 
levels for Trim30a-CypA and Trim30b-CypA were much higher than were those 212 
for the Trim12 fusion proteins. Restriction activity of Trim12A-CypA was not due 213 
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to non-specific activation of an antiviral state in that this protein had no effect on 214 
transduction by Moloney murine leukemia virus (Fig. 3F); the capsid of this virus 215 
is not recognized by CypA (24). Taken together, these results indicate that 216 
restriction activity requires CA recognition and the ability to stimulate AP-1 217 
luciferase activity. 218 
 219 
TAK1 is required for activation of the MAPK pathway by mouse TRIM5 220 
orthologues. Activation of innate immune signaling by human TRIM5 can be 221 
prevented by 5Z-7-oxozeaenol, a specific inhibitor of TGF-beta activated kinase 222 
1 (TAK1 or MAP3K7) (15). To determine if TAK1 is required for activation of 223 
innate immune signaling by the murine Trim5 homologues, HEK293 cells were 224 
transfected with expression plasmids for the Trim12 genes in the presence of 5Z-225 
7-oxozeaenol. AP-1 luciferase activity associated with Trim12a was decreased 5-226 
fold by the kinase inhibitor (Fig. 4A). With either Trim12b or Trim12c, the kinase 227 
inhibitor decreased AP-1 activity 11-fold (Fig. 4A). 228 
Genetic evidence for the importance of TAK1 was obtained by stable 229 
transduction of HEK293 cells using a previously described lentiviral vector that 230 
expresses a puromycin resistance gene and miR30 modified to knockdown TAK1 231 
(15, 16). A vector targeting irrelevant sequences was used as a control. The two 232 
pools of puromycin-resistant cells were transfected with increasing amounts of 233 
the Trim12 expression plasmids. TAK1 KD reduced AP-1 induction by Trim12a 234 
20-fold and induction by Trim12c 25-fold (Fig. 4B). The combination of TAK1 235 
knockdown with overexpression of Trim12b proved too toxic to permit meaningful 236 
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analysis of the results. Taken together, these results indicate that the murine 237 
TRIM5 orthologues stimulate innate immune signaling through TAK1. 238 
 239 
TAK1 is required for HIV-1 restriction by murine Trim12-cyclophilin A 240 
fusion proteins. To determine if HIV-1 restriction by murine Trim12-cyclophilin A 241 
fusion proteins requires innate immune signaling, doubly-transduced HEK293 242 
cell lines were generated, using vectors as described previously (25). The first 243 
round of transduction was with hygromycin-resistance conferring, miR30 244 
knockdown vectors targeting TAK1 or control, followed by transduction with 245 
puromycin-resistance conferring vectors expressing the Trim12-CypA fusion 246 
genes. The pools of hygromycin-, puromycin- double-resistant cells transduced 247 
with Trim12b-CypA grew poorly and could not be assessed further. The 248 
remaining pools of doubly-resistant cell lines were then challenged with a VSV G-249 
pseudotyped, env-minus, HIV-GFP vector. Trim12A-CypA and Trim12C-CypA 250 
restricted HIV-1 transduction between 5 to 10-fold, as compared with cells 251 
transduced with the empty puromycin resistant expression vector, in the 252 
presence of the control knockdown construct (Fig. 4C). In contrast, cells 253 
expressing the TAK1 shRNAmir did not inhibit HIV-1 transduction, indicating that 254 
TAK1 was required for Trim12a-CypA and Trim12c-CypA restriction activity.255 
                                                                                                                             Lascano et al 13
DISCUSSION 256 
 257 
Here we tested 18 TRIM family members for the ability to activate innate immune 258 
signaling. Among these, six out of six primate TRIM5 orthologues had the ability 259 
to activate AP-1 signal transduction (Fig. 1A). The primate TRIM5 proteins were 260 
selected from both Old World and New World primates and included proteins that 261 
utilize a PRY-SPRY domain or a CypA domain to recognize the incoming capsid 262 
lattice. Each of these TRIM5 proteins is capable of restricting retroviruses, 263 
though their capsid specificities are quite diverse. For example, owl monkey 264 
TRIM5-CypA and rhesus TRIM5α potently blocking HIV-1 transduction (26-28), 265 
while rhesus TRIM5-CypA and human TRIM5α have minimal activity against this 266 
virus (26, 29-31). Instead, rhesus TRIM5-CypA potently restricts HIV-2 (29, 31) 267 
and human TRIM5a potently restricts N-tropic MLV or EIAV (32-35). 268 
 269 
Among Carnivora, the TRIM5 gene in dogs was disrupted by insertion of a 270 
retrotransposed PNRC1 pseudogene (36). Cats have a TRIM5 gene but it lacks 271 
coding sequence for the C-terminal CA-binding domain (36). Nonetheless, when 272 
fused to the HIV-1 CA binding protein CypA, the feline orthologue has potent 273 
HIV-1 restriction activity (37). Feline TRIM5 was tested here and also found to 274 
activate AP-1 signaling (Fig. 1A). In contrast, the three closest human paralogues 275 
of TRIM5, TRIM6, TRIM22, and TRIM34 do not activate AP-1 signaling (Fig.1B). 276 
Interestingly, TRIM25, a paralogue that is required for RIG-I-mediated signal 277 
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transduction (19) and that generates K63-ubiquitin chains like TRIM5 (38) also 278 
activates AP-1 signaling.  279 
 280 
Among the seven mouse Trim5 homologues tested here, Trim12a, b, and c all 281 
activated innate immune signaling and the Trim30 proteins did not (Fig. 1c). An 282 
obvious question of interest is which residues in these proteins explain the 283 
differences in activity. To address this issue, a panel of chimeras was generated 284 
in which domains were swapped between Trim12a and Trim30a. These two 285 
proteins possess 60% amino acid identity (Supplementary FIG 1). Unfortunately, 286 
the activity could not be pinpointed to specific amino acid residues or even to a 287 
specific domain. This kind of mapping has been difficult with TRIM5 proteins, as 288 
observed previously (12, 15). 289 
 290 
According to Tareen et al, and confirmed by us, none of the murine Trim5 291 
homologues had restriction activity against any of eight different retroviral vectors 292 
(18). For Trim12a and Trim30b, absence of retroviral restriction activity is not 293 
surprising given that these genes encode only the core Trim5 RBCC isoform 294 
(RING, B box, and coiled-coil domain) and lack a C-terminal CA-binding domain 295 
(Table 1). For the other homologues that possess a C-terminal PRYSPRY 296 
domain (Trim12b and c, and Trim30a, c, and d), lack of restriction activity could 297 
be because the encoded proteins actually lack restriction activity or simply 298 
because a restriction sensitive retrovirus has not yet been identified. To bypass 299 
our ignorance regarding this question the HIV-1 CA-binding protein CypA was 300 
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fused via flexible linker to the C-terminus of the RBCC portion of each of the 301 
murine Trim5 homologues (Fig. 3C), as we and others have done previously (21, 302 
22). Among the fusion proteins, only those Trim5 homologues that activated AP-303 
1 signaling exhibited HIV-1 restriction activity. It is of note that those murine 304 
Trim5 homologues that activated innate immune signaling, and that when fused 305 
to CypA had HIV-1-specific restriction activity, formed discrete cytoplasmic 306 
bodies without any diffuse cytoplasmic signal (Fig. 2). This was not the case with 307 
the Trim30 proteins. Similar correlation of restriction activity with the ability to 308 
form only discrete cytoplasmic bodies was reported previously with a panel of 309 
engineered human TRIM5-CypA fusion proteins (22). Thus, the ability to activate 310 
innate immune signaling, and to form discrete cytoplasmic bodies, appears to be 311 
required for TRIM5-mediated retrovirus restriction. 312 
 313 
Despite the fact that we and others were unable to identify a retrovirus that is 314 
restricted by the murine Trim5 homologues, signatures of positive selection have 315 
been reported in the mouse genes (18), suggesting that the selective pressure 316 
for Trim5 expansion derives from challenge with retroviruses, as believed to be 317 
the case with primate TRIM5 (2). But why did the murine Trim5 locus expand so 318 
enormously? One obvious difference between mice and human is that, in 319 
humans there are no known replication competent, endogenous retroviruses, 320 
whereas in mice there are many endogenous retroviruses with the ability to 321 
replicate and mutate the mouse genome (39). 322 
 323 
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Disruption of TAK1 by either a pharmacologic inhibitor or by knockdown 324 
prevented AP-1 activation by the murine Trim12 proteins (Fig. 4A and B). 325 
Similarly, TAK1 knockdown prevented the Trim12-CypA fusion proteins from 326 
restricting HIV-1 (Fig. 4C). TAK1 had been shown to co-precipitate with TRIM5 327 
and to be activated by the free K63 ubiquitin chains that TRIM5 synthesizes in 328 
the presence of the heterodimeric E2 enzymes UEV1A and UBC13 (15). These 329 
findings suggested that TRIM5 acts as an innate immune, pattern recognition 330 
receptor specific for the capsid lattice. Recognition of antibodies that have been 331 
brought into the cytoplasm attached to viruses stimulates TRIM21 to synthesize 332 
K63-linked ubiquitin chains that activate TAK1 (38). In an analogous fashion it 333 
has been reported that blockade of nascent virion budding by TETHERIN/BST2 334 
activates TAK1-dependent innate immune signaling (40, 41), as does the long 335 
cytoplasmic tail of HIV-1 gp41 (42) or the HIV-1 accesory protein Vpr (42). In the 336 
case of TRIM5 and TETHERIN/BST2, innate immune signaling seems to act as a 337 
danger signal. In contrast, activation of TAK1 by gp41 or Vpr seems to stimulate 338 
transcription from the HIV-1 LTR.  339 
 340 
TRIM5 co-immunoprecipitates with TAB2 and TAB3, co-activators for TAK1 (15). 341 
Interestingly, TAB2 and TAB3 associate with BECLIN1 and by doing so inhibit 342 
autophagy (43). TRIM5 also associates with p62, BECLIN, and other 343 
components of the autophagy machinery (11, 12). How all these interactions 344 
might contribute to the TRIM5 retrovirus restriction mechanism is not clear, 345 
though it has been proposed that TRIM5 acts as a cargo receptor that promotes 346 
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the selective degradation of HIV-1 capsid by autophagy (12). Perhaps by 347 
generating free K63-linked ubiquitin chains TRIM5 removes the TAB proteins 348 
from BECLIN1 and promotes their transfer to an activated TAK1 (15). By freeing 349 
BECLIN1 from the TABs, autophagy would be activated (43). Another possibility 350 
is that Tak1 regulates Trim5 stability via effects on ubiquitin machinery (43). 351 
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MATERIALS AND METHODS 352 
Drugs, reagents and antibodies. The TAK-1 inhibitor, 5Z-7-oxoeaenol (Sigma), 353 
was diluted in dimethylsulfoxide (DMSO) and used at a concentration of 300 nM. 354 
Puromycin and hygromycin (Sigma) were used at 5 μg/ml and 50 μg/ml, 355 
respectively. Mouse anti-c-Myc and anti-β-actin antibodies were from Sigma. 356 
Rabbit anti-TAK1 and anti-β-tubulin antibodies were from Cell Signaling 357 
Technologies. 358 
Cell lines. HEK-293, CRFK, and C57BL6J MEF cell lines were maintained in 359 
high glucose Dulbecco’s modified Eagle medium (D-MEM) (Invitrogen) 360 
supplemented with L-glutamine (2 mM), penicillin (100 units/ml), streptomycin 361 
(100 μg/ml) (GIBCO) and FBS (10%) (PAA). 362 
Cloning and plasmids. The sequences of primers used for cloning are shown in 363 
Supplementary Tables 1 and 2. Human and non-human primate TRIM5 364 
orthologues were PCR amplified from previously described plasmid templates 365 
(15, 20, 27, 31). Feline TRIM5 was amplified by RT-PCR from CRFK cell RNA. 366 
Human TRIM5 paralogues were amplified from human macrophage RNA. Murine 367 
Trim5 orthologues were amplified from C57BL/6J murine embryonic fibroblast or 368 
splenic T cell RNA. Murine Trim5 orthologue fusions to cyclophilin A were 369 
generated by overlapping PCR using each mouse Trim and the cyclophilin A 370 
domain from owl monkey TRIM5Cyp (27), as templates. 371 
Using standard methods, TRIM5 homologues and fusion proteins were 372 
cloned into expression plasmid pcDNA3.1(-) (Invitrogen) or into pFUPI which 373 
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encodes an HIV-1 based, lentiviral genome with an internal ubiquitin promoter 374 
driving expression of a puromycin resistance cassette followed by the ECMV 375 
IRES (22). The coding sequences of interest were all cloned 3’ of the IRES. 376 
pWPTs-GFP is an HIV-1-based transfer vector with EGFP expression 377 
under the control of the EF1α promoter; psPAX2 and pMD2.G encode HIV-1 378 
gag-pol and the vesicular stomatitis virus glycoprotein, respectively. (44). HIV-1-379 
GFP has a frameshift mutation in env and nef is replaced with GFP (45). pLNC-380 
GFP and pCG-gagpol are Moloney murine leukemia virus genome and gag-pol 381 
plasmids, respectively. The Prl promoter AP-1-luc construct was a gift from Dr. 382 
Ruslan Medzhitov (Yale School of Medicine). 383 
 384 
Transfection and vector production. FUPI three parts virus was 385 
obtained by transfecting 293FT cells, plated in 10cm plates, with pFUPI plasmid 386 
containing either no insert or different TRIM-Cyp constructs, psPAX2 (gagpol) 387 
and pMD2G (envelope) plasmids (22). HIV-1-GFP three part vectors were 388 
prepared by transfecting HEK293 cells in 10 cm plates with pWPTS-GFP, 389 
psPAX2, and pMD2.G at a ratio of 3:2:1, using Lipofectamine 2000 (Invitrogen) 390 
or polyethylenimine (PEI) (Sigma Inc). 30 μg of DNA were mixed with 60 μl of 391 
lipofectamine 2000 or PEI (1 mg/ml) in 1 ml of Opti-MEM (Invitrogen) and 392 
incubated for 30 mins and added to the cells. At 48 hrs post-transfection, virus 393 
supernatants were harvested. 394 
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Transduction assays. CRFK cells expressing Trim-CypA fusions or empty 395 
vector were seeded at a density of 1.5 x 103 cells/well in a 96-well. HEK293 cells 396 
stably co-expressing Trim-CypA fusions and NT or TAK1 shRNAmir were seeded 397 
at a density of 2 x 105 cells/well in a 48-well plate. 24 hrs later the cells were 398 
infected with serial dilutions of HIV-1- or MLV-GFP viruses as indicated. 48 hrs 399 
post-transduction the percentage of infected (GFP-positive) cells was determined 400 
by flow cytometry. 401 
Luciferase transcription reporter assays. HEK293 cells were seeded on white 402 
96-well plates (Perkin-Elmer) at a density of 2.5 x 104 cells per well. 24 hrs later, 403 
cells were transfected with 25 ng of firefly-luciferase reporter plasmid, 5 ng of the 404 
internal control reporter plasmid pRL-TK (Promega) and 25 to 50 ng of the 405 
pcDNA3-1(-) plasmid containing a cDNA of interest, or the empty plasmid, using 406 
Lipofectamine 2000. 48 hrs post-transfection, cells were lysed and assayed with 407 
the Dual-Glo luciferase system (Promega), according to the manufacturer’s 408 
instructions. The luciferase activity of each well was measured using the Veritas 409 
Microplate Luminometer (Turner Biosystem). For each well, the Firefly luciferase 410 
activity was normalized to the Renilla luciferase reading and plotted as a fold-411 
induction, compared to the empty pcDNA3.1 (-). Each condition was performed in 412 
quintuplicate. 413 
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Immunofluorescence. HEK293 cells were transfected using FUGENE6 414 
(Promega) with 10 ng of myc-tagged murine TRIM5 orthologues expression 415 
constructs in a poly-lysine coated 8-well Nunc® Lab-Tek® II 1.5 borosilicate 416 
cover-glass bottom chambers and fixed after 24-36 hr with 4% 417 
paraformaldehyde. Murine TRIM5 orthologues-myc were visualized using rabbit 418 
monoclonal antibodies to the myc-tag (1:2,000 dilution; Sigma-Aldrich), followed 419 
by secondary antibodies to rabbit immunoglobulin conjugated to Alexa Fluor 488 420 
(1:5,000 dilution; Invitrogen). Nuclei were stained with propidium iodide. Images 421 
were acquired by using a 60X objective lens (NA 1.4) on a Volocity spinning disc 422 
confocal microscope with z-spacing of 0.15 μm and processed using the Volocity 423 
software package 6.3.1 (Perkin-Elmer). Z-sections were combined to flatten and 424 
obtain extended focus images. 425 
  426 
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FIGURE LEGENDS 588 
 589 
FIG 1 AP-1 induction by TRIM5 orthologues and paralogues. HEK-293 cells were 590 
transfected in quintuplicate with an AP-1-firefly luciferase reporter plasmid, a TK-591 
renilla luciferase plasmid as transfection control, in combination with an 592 
expression plasmid for the indicated primate TRIM5 orthologues (A), the 593 
indicated Homo sapiens TRIM5 paralogues (B), or the indicated Mus musculus 594 
TRIM5 orthologues (C). 48 hrs later, firefly luciferase activity was measured and 595 
normalized to renilla luciferase in each sample. Bars show the mean +/- the 596 
standard deviation. (D) Expression plasmids for the seven Mus musculus TRIM5 597 
orthologues, each with a C-terminal myc-epitope tag, were transfected into 598 
HEK293 cells. At 48 hrs the cell lysate was probed by western blot with anti-myc 599 
or anti-actin antibodies. Hs, Homo sapiens; Mam, Macaca mulatta; Ct, 600 
Cercopithecus tantalus; Ca, Cercopithecus aethiops; At, Aotus trivirgatus; Mn, 601 
Macaca nemestrina; Mm, Mus musculus; Cyp, cyclophilin A. 602 
 603 
FIG 2 Intracellular location of Mus musculus TRIM5 orthologues. The panels 604 
show confocal microscopy images of the indicated myc-tagged TRIM5 mouse 605 
orthologues (green), transiently expressed in HEK293 cells and immunolocalized 606 
with antibodies to the myc epitope and propidium iodide stained nuclei (red). Z-607 
sections were combined to flatten and obtain extended focus image. Selected y-z 608 
and x-z slices are also shown. Scale bars equal 17 μm. 609 
 610 
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FIG 3 Characterization of Mus musculus TRIM5 orthologue-cyclophilin A fusions. 611 
HEK-293 cells were transfected with AP-1-firefly luciferase and TK-renilla 612 
luciferase plasmids, as in Fig. 1, along with the indicated Mus musculus TRIM5 613 
orthologue-cyclophilin A fusions (A and B). 48 hrs later, firefly luciferase activity 614 
was measured, normalized to renilla luciferase, and plotted for the mean +/- 615 
standard deviation. (C) Schematic diagram showing structure of the lentiviral 616 
vector genomic RNA used in D and E for stable expression of Mus musculus 617 
TRIM5 orthologue-cyclophilin A fusion genes. (D-F) CRFK cells were transduced 618 
with lentiviral vectors expressing the indicated Mus musculus TRIM5 orthologue-619 
cyclophilin A fusions and selected in pools with puromycin. Three-part, env-620 
minus, HIV-1-GFP vector (D and E), or MLV-GFP vector (F), were pseudotyped 621 
with VSV glycoprotein and titrated on the transduced CRFK cells. 48 hrs later the 622 
percent GFP-positive cells was determined by flow cytometry. 623 
 624 
FIG 4 TAK1 is required for AP-1 induction by Mus musculus Trim12 genes and 625 
for HIV-1 restriction activity of Mus musculus Trim12 gene-cyclophilin A fusions. 626 
The effect of the TAK1 inhibitor 5z-7-Oxozeaenol (A), or of TAK1 knockdown (B), 627 
on AP-1 luciferase activity was determined after transfection with the indicated 628 
Trim12 expression plasmids, as in Fig. 1. For the knockdown, HEK293 cells were 629 
transduced with a lentiviral knockdown vector targeting TAK1, or a control vector 630 
(NT). In each case, pools of transduced HEK293 cells were selected for 631 
blasticidin resistance. (C) HIV-1-GFP transduction of HEK293 cells stably 632 
expressing the indicated Trim12-CypA fusion genes, along with shRNAs 633 
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targeting TAK1 or control. Infectivity was measured as in Fig. 3. The error bars 634 
indicate standard deviation in HIV-1 transduction from two experiments, each 635 
carried out in triplicate.  636 
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 637 
TABLE 1: The murine TRIM5 orthologues studied here 638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
 646 
 647 
 648 
 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
Gene 
name 
Alternative gene 
names 
Accession 
numbers 
Protein domains 
Trim12a Trim12 
2310043C01Rik 
NM_023835.2 RBCC 
Trim12b 
 
Trim5 
Gm8833 EG667823 
XM_992714.5 RBCC-PRYSPRY 
Trim12c 
 
Trim12-2; 
9230105E10Rik 
NM_175677.4 RBCC-PRYSPRY 
Trim30a Rpt1 
Trim30 
NM_009099.2 RBCC-PRYSPRY 
Trim30b 
 
Trim30-1 
A530023O14Rik 
AK040770.1 RBCC 
Trim30c 
 
Trim30-2; Gm5598; 
EG434219;  
XR_378392.1 RBCC-PRYSPRY 
Trim30d 
 
TRIM30-3; Trim79; 
AI451617;  
NM_199146.2 RBCC-PRYSPRY 




